"One of my main concerns is that they're long-term adverse events for which we really don't have much data, especially for those who are taking them just for weight loss and not for diabetes." People with diabetes were not included in the study
Meta-analyses of these and other studies have demonstrated: Reductions in total cholesterol typically in the range of 15% from baseline, varying by agent and population Decreases in LDL cholesterol ranging from 17%, generally more modest than dedicated lipid-lowering therapies Reductions in triglycerides of 515%, with greater effects often seen in those with higher baseline levels Variable effects on HDL cholesterol , with small increases (1-2%) or neutral effects reported The magnitude of lipid improvements appears to correlate with the degree of weight loss achieved, suggesting that metabolic benefits may be partially mediated through adiposity reduction
In fact, our manager will contact you after the treatment to make sure that you are happy with the results
[4] [6] It is also contraindicated in patients with a prior serious hypersensitivity reaction to tirzepatide or any of the product components
IDF Diabetes Atlas 9th Edition
Research into AOD-9604 has also explored its cartilage and bone metabolism properties in animal models